ARTICLE | Clinical News

Demcizumab: Additional Phase Ib data

January 20, 2014 8:00 AM UTC

Data from 6 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, international Phase Ib trial showed that first-line treatment with IV demcizumab plus gemcitabine and Abraxane nab-paclitaxel led to 3 partial responses and 2 cases of stable disease. The combination was generally well tolerated with fatigue, hypertension, nausea and vomiting reported as the most common treatment-related toxicities. No demcizumab-related reversible cardiotoxicity events occurred. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium in San Francisco.

In October, OncoMed reported data from 16 evaluable patients who received first-line treatment with demcizumab plus gemcitabine in the trial (see BioCentury, Nov. 4, 2013). The trial includes a risk mitigation plan that includes cardiac monitoring using B-type natriuretic peptide (BNP; NPPB) testing and echocardiography as well as intervention with cardioprotective medication such as an angiotensin-converting enzyme (ACE) inhibitor in patients with rising BNP levels. Next half, OncoMed plans to start a Phase II trial of demcizumab plus gemcitabine and Abraxane as first-line treatment of advanced pancreatic cancer. ...